Virus Specific T-Cell
Identification
- Generic Name
- Virus Specific T-Cell
- DrugBank Accession Number
- DB15735
- Background
Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation. These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs. In some cases, the cells are created from blood samples of patients who have recovered from viral infections.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Cell transplant therapies
Autologous cell transplant / Other cell transplant therapies - Synonyms
- HLA-matched Virus Specific T Cells
- Partially HLA-matched Virus Specific T Cell
- Viral Specific T-lymphocytes
- VST
- External IDs
- Virus Specific T-Cell
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
Administration of VSTs can provide physiological protection against specific infections, especially for patients who are immunocompromised and depleted of T-cells. VSTs are used as an immunotherapy against many infections, including Epstein-Barr virus, adenovirus, BK virus, and human herpesvirus type 6. This type of treatment is also being investigated as a therapy against SARS-Cov-2.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Houghtelin A, Bollard CM: Virus-Specific T Cells for the Immunocompromised Patient. Front Immunol. 2017 Oct 11;8:1272. doi: 10.3389/fimmu.2017.01272. eCollection 2017. [Article]
- Barrett AJ, Prockop S, Bollard CM: Virus-Specific T Cells: Broadening Applicability. Biol Blood Marrow Transplant. 2018 Jan;24(1):13-18. doi: 10.1016/j.bbmt.2017.10.004. Epub 2017 Oct 12. [Article]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Withdrawn Treatment Coronavirus Disease 2019 (COVID‑19) / Viral Infections 1 1 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / Viral Infections 1 1, 2 Active Not Recruiting Treatment Adenovirus Infections / Cytomegalovirus (CMV) Infection / Epstein Barr Virus Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on August 11, 2020 20:16 / Updated on August 13, 2020 07:02